ArthroCare makes Fitzgerald permanent head
This article was originally published in Clinica
Executive Summary
David Fitzgerald, who has been serving as interim president and CEO for minimally-invasive surgical technologies developer ArthroCare since February, has taken up the role on a permanent basis. Mr Fitzgerald joined ArthroCare's board of directors in 2003 – his career includes 25 years at Pfizer, of which the last 15 were spent as president and CEO of its Howmedica Orthopedics division. He took the helm of Austin, Texas-based ArthroCare after its previous president and CEO Michael Baker stepped down following an internal audit of the company which found evidence of improper business practices by its staff (www.clinica.co.uk, February 19 2009).
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.